Skip to main
DYN

Dyne Therapeutics (DYN) Stock Forecast & Price Target

Dyne Therapeutics (DYN) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 50%
Buy 42%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Dyne Therapeutics is expected to see success in developing treatments for a wide range of serious neuromuscular diseases by utilizing its proprietary FORCE platform, with a potential BLA submission for their first commercial product in 3Q27. They have a strong financial position, with a cash runway into 1Q28 and a 12-month price target of $38 per share. However, there are risks, including the need for future fundraising, competition from other companies in the oligonucleotide therapy space, and the potential for slower market penetration.

Bears say

Dyne Therapeutics is a development stage company that currently does not have any products that generate revenue. This, coupled with its high cash burn rate, leads to a negative outlook on the stock. Additionally, the company will likely need to raise more capital in the future, which may dilute the stock and involve restrictive covenants. The success of the company's pipeline is also uncertain and faces competition from larger, more established companies in the gene therapy/oligonucleotide space. Until the company achieves significant milestones, its valuation is difficult to accurately determine, making it a risky investment.

Dyne Therapeutics (DYN) has been analyzed by 12 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 42% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dyne Therapeutics (DYN) Forecast

Analysts have given Dyne Therapeutics (DYN) a Buy based on their latest research and market trends.

According to 12 analysts, Dyne Therapeutics (DYN) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dyne Therapeutics (DYN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.